Eosinophilic Esophagitis Prevalence May Be Higher Than Thought in Pediatric Patients With Asthma

THURSDAY, July 30, 2026 (HealthDay News) -- Screening for eosinophilic esophagitis (EoE) in a pediatric asthma clinic may identify more patients than previously thought, according to a study published online June 23 in JACI: In Practice.Robert E. Becker, M.D., from Medical College of Wisconsin in Milwaukee, and colleagues estimated the prevalence of EoE among pediatric patients with asthma using noninvasive screening. The analysis included responses to a modified Pediatric Eosinophilic Esophagitis Symptom Severity v2.0 survey administered to 189 patients with asthma (age, 7 to 17 years) or parents of patients with asthma (age, 3 to 6 years) seen in a tertiary care center’s asthma and allergy clinic.The researchers found that 80.4 percent screened positive, and of these, 47.4 percent were referred to gastroenterology. Of those referred, 61.1 percent completed the referral. Among the 24 who underwent endoscopy, one-third were diagnosed with EoE. Among patients with asthma in the asthma and allergy clinic population, the total projected prevalence of EoE was 8.0 percent, with prevalence rising to 13.9 percent when accounting for nonparticipants and those lost to follow-up. The only individual screening symptom significantly associated with EoE diagnosis was vomiting. "Screening in a pediatric asthma clinic identified a previously unrecognized high prevalence of EoE," the authors write. "This approach may facilitate earlier diagnosis, prevent fibrostenotic complications, and reduce racial disparities."Abstract/Full Text (subscription or payment may be required).Sign up for our weekly HealthDay newsletter

Eosinophilic Esophagitis Prevalence May Be Higher Than Thought in Pediatric Patients With Asthma

Related Stories

Emergency Room AI Identifies PTSD Risk Through Patient Stories

Inpatient Rehab, Nursing Facility Or Home? How To Choose The Right Rehab After A Hospital Stay

Patient Reps on FDA Committees Often Have Pharma Ties

FDA Patient, Consumer Reps Often Tied To Pharma-Funded Groups